Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | LDLR | P01130 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.43 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.43 |
| ▸ | MAP3K2 | Q9Y2U5 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868271 | 0.93 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2MAPK14KIT | |
| SCHEMBL2863438 | 0.85 | MEN1 (0.56) | TAS1R3TAS1R1TAS1R2KITMEN1 | |
| SCHEMBL2858442 | 0.83 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2857149 | 0.81 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2MAPK14MEN1 | |
| SCHEMBL10720889 | 0.80 | CXCR4 (0.65) | MAPK14KITCXCR4MEN1KMT2A | |
| SCHEMBL2856419 | 0.78 | TAS1R3 (0.67) | TAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL2863458 | 0.78 | TAS1R3 (0.53) | TAS1R3TAS1R1TAS1R2MAPK14MEN1 | |
| SCHEMBL22919723 | 0.77 | CXCR4 (0.61) | MAPK14KITCXCR4MEN1KMT2A | |
| SCHEMBL8393231 | 0.76 | SMN1; SMN2 (0.64) | MAPK14KITCXCR4HDAC6MAPK11 | |
| SCHEMBL8391413 | 0.76 | SMN1; SMN2 (0.64) | MAPK14KITCXCR4HDAC6MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | NAAA, NAT1, SAT1 | TAS1R3 4053/4885TAS1R1 3002/4885TAS1R2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.